It was reported that the survival rate of patients with lung cancer decreased when ANXA2 was up-regulated, which might serve as a potentail biomarker for NSCLC (Agababaoglu et al., 2017; Wang et al., 2012). Here, ANXA2 is linked to non-small cell lung carcinoma.